Metagenomic analysis of the human microbiome

Bermúdez‐Humarán, Luis G.

doi:10.1002/9781118982907.ch6

Cited by 2 publications

(1 citation statement)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of strategies to enhance innate immune responses to target and eliminate tumor cells have been studied or are currently under investigation [75,76]. Therapeutic live vaccines targeting HPV have been developed using bacterial vectors from a variety of bacterial species [77][78][79]. Listeria is a particularly promising vector due to its ability to avoid phagocytosis by macrophages and it is presented on both MHC class I to cytotoxic T cells and MHC class II to helper T cells [80].…”

Section: Therapeutic Vaccines Antibody Drug Conjugates and Tumor Infiltrating Lymphocyte Therapymentioning

confidence: 99%

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy

Cohen

Roane

Leath

2020

Drugs

View full text Add to dashboard Cite

While screening programs and HPV vaccination have decreased the incidence of cervical cancer, still over 13,000 cases occur in the United States annually. Early stage cervical cancer has an excellent long-term prognosis, with 5-year survival for localized disease being >90%. Survival decreases markedly for both locally advanced and metastatic disease, and both are associated with a higher risk of recurrence. Few effective treatment options exist for persistent, recurrent, or metastatic cervical cancer. In 2014, the anti-VEGF antibody bevacizumab was approved in combination with chemotherapy based on the results of the phase III GOG-240 study. As the majority of cervical cancers have a viral etiology, which impairs the immune system, immunotherapy using checkpoint inhibitors and other agents, appears to be a promising approach. In June 2018, the US FDA approved the anti-PD1 antibody pembrolizumab for recurrent or metastatic cervical cancer with PD-L1 expression that progressed after one or more lines of chemotherapy. Another anti-PD1 antibody, cemiplimab also shows potential in this setting, either as monotherapy or combined with radiotherapy, and it is currently being evaluated in a phase III trial. Additional checkpoint inhibitors including nivolumab, durvalumab, atezolizumab, and camrelizumab are in different stages of clinical development for the disease. Finally, an additional targeted approach being pursued are PARP inhibitors (rucaparib and olaparib are both in phase II) based on earlier study results.

show abstract

Section: Therapeutic Vaccines Antibody Drug Conjugates and Tumor Infiltrating Lymphocyte Therapymentioning

confidence: 99%